{"organizations": [], "uuid": "2be44edb655525c46f984efb0e9291347f2a66cd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/10/04/104751921-Activa_PC_Placement_blue.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/19854910/device/rss/rss.html", "section_title": "Tech", "url": "https://www.cnbc.com/2018/02/20/medtronics-quarterly-profit-meets-expectations.html", "country": "US", "domain_rank": 767, "title": "Medtronic's quarterly profit meets expectations", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-20T14:51:00.000+02:00", "replies_count": 0, "uuid": "2be44edb655525c46f984efb0e9291347f2a66cd"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/20/medtronics-quarterly-profit-meets-expectations.html", "ord_in_thread": 0, "title": "Medtronic's quarterly profit meets expectations", "locations": [], "entities": {"persons": [{"name": "s. medtronic", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "ireland", "sentiment": "none"}], "organizations": [{"name": "medtronic", "sentiment": "negative"}, {"name": "covidien", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Largest U.S. standalone medical device maker Medtronic reported a third-quarter profit in-line with analysts' estimates, as sales across all its units, except the minimally invasive therapies business, grew.\nSales in its cardiac and vascular unit which sells defibrillators, pace-makers, heart valves and stents jumped 10 percent to $2.8 billion, accounting for nearly 40 percent of its total sales.\nThe minimally invasive therapies business, which the company acquired as part of its $42.9 billion deal to buy Covidien in 2015, generated sales of $2.04 billion, a 16 percent fall from the year-ago quarter.\nExcluding items, Medtronic earned $1.17 per share in the quarter, in-line with analysts' estimates, according to Thomson Reuters I/B/E/S.\nMedtronic, which redomiciled to Ireland through its Covidien deal, said it saw a $2.2 billion net charge related to recent changes in the U.S. tax laws.\nThe company reported a third-quarter loss of $1.39 billion, or $1.03 per share, in the quarter ended Jan. 26, compared with a profit of $821 million, or $0.59 per share, a year earlier.\nNet sales rose 1.2 percent to $7.37 billion, beating estimates of $7.21 billion.", "external_links": [], "published": "2018-02-20T14:51:00.000+02:00", "crawled": "2018-02-20T15:00:19.000+02:00", "highlightTitle": ""}